Ginseng Compound Targets Mitochondrial Protein to Slow Brain Aging
Ginsenoside Re binds a conserved site on Drp1 to restore mitochondrial fission and clear cellular debris, extending healthspan in multiple species.
Résumé
Researchers identified ginsenoside Re (Re), a compound from ginseng, as a potent neuroprotective agent that crosses the blood-brain barrier and targets mitochondria. Re binds directly to the Leu94 residue of Drp1, a protein controlling mitochondrial fission, triggering a signaling cascade that restores the balance between mitochondrial splitting and fusion. This also activates mitophagy — the cellular cleanup of damaged mitochondria — via the Drp1-Atg1/ULK1 pathway. Tested in Drosophila, mice, and human iPSC-derived dopaminergic neurons, Re reduced neuronal loss, improved motor and cognitive function, and extended healthspan. Critically, these benefits were abolished when the Drp1 L94 site was genetically removed, confirming the mechanism's specificity.
Résumé détaillé
Mitochondrial dysfunction is a central driver of brain aging and neurodegenerative diseases like Parkinson's. As cells age, mitochondria lose their normal fission-fusion balance, accumulating damage that impairs energy production and neuronal survival. Safe, targeted therapies to correct this remain scarce.
This study screened ginseng-derived saponins for blood-brain barrier permeability and neuroprotective efficacy, identifying ginsenoside Re as the top candidate. Researchers then investigated its mechanism across multiple biological models including Drosophila, mice, and human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons — the cell type most vulnerable in Parkinson's disease.
Re was found to directly bind the conserved Leu94 residue on Drp1, the master regulator of mitochondrial fission. This binding triggers phosphorylation at Drp1's S616 site, prompting Drp1 to translocate to mitochondria and restore healthy fission-fusion equilibrium. Re also spatiotemporally couples fission to mitophagy through the Drp1-Atg1/ULK1 axis, ensuring that freshly fragmented, damaged mitochondria are efficiently tagged and degraded. This dual action boosts cellular energy capacity and clears dysfunctional organelles.
Administering Re during midlife — a window when mitochondrial hyperfusion naturally emerges — rescued age-related neurodegeneration in flies, preserved dopaminergic neurons, reduced muscle pathology, improved cognition and motor function, and extended healthspan. Genetic deletion of Drp1 L94 completely abolished all benefits, confirming mechanistic specificity. Results were replicated in mice and human iPSC neurons, suggesting strong cross-species conservation.
While promising, this remains preclinical work. Human clinical trials are needed to confirm safety, bioavailability, and efficacy. The optimal dosing window (midlife intervention) also raises translational questions about how to identify and time treatment in humans.
Principales conclusions
- Ginsenoside Re binds the conserved Drp1 Leu94 residue, triggering S616 phosphorylation and restoring mitochondrial fission-fusion balance.
- Re couples mitochondrial fission to mitophagy via the Drp1-Atg1/ULK1 axis, enabling efficient clearance of damaged mitochondria.
- Midlife Re treatment in Drosophila reduced dopaminergic neuron loss, improved cognition and motor function, and extended healthspan.
- Genetic ablation of Drp1 L94 completely abolished Re's neuroprotective and healthspan-extending effects, confirming target specificity.
- Neuroprotective effects were conserved across Drosophila, mice, and human iPSC-derived dopaminergic neurons.
Méthodologie
The study used Drosophila aging and Parkinson's models, mouse translational studies, and human iPSC-derived dopaminergic neurons. Molecular docking and genetic ablation of Drp1 L94 were used to confirm the binding mechanism. Re was administered during a defined midlife intervention window aligned with natural mitochondrial hyperfusion.
Limites de l'étude
All efficacy data are from animal and cell models; no human clinical trials have been conducted. The optimal midlife intervention timing may be difficult to define and implement clinically. Bioavailability, dosing, and long-term safety of ginsenoside Re in humans remain uncharacterized.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :